Matthew S. McIlwain - 23 Jun 2025 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role: Director
Signature: /s/ Mathew B. Murphy, as Attorney-in-Fact
Issuer symbol: NAUT
Transactions as of: 23 Jun 2025
Transactions value $: $0
Form type: 4
Date filed: 25 Jun 2025, 16:37
Previous filing: 24 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
McIlwain Matthew S	Director	C/O NAUTILUS BIOTECHNOLOGY, INC., 2701 EASTLAKE AVE. E., SEATTLE	/s/ Mathew B. Murphy, as Attorney-in-Fact	2025-06-24	0001381752

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NAUT	Stock Option (Right to Buy)	Award	$0	+45K		$0.00	45K	23 Jun 2025	Common Stock	45K	$0.70	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Content

Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).